Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Research brief (Leonard Davis Institute of Health Economics)
- Author(s):
- Doshi, Jalpa A., author Puckett, Justin T., author Parmacek, Michael S., author Rader, Daniel J., author
- Contributor(s):
- Leonard Davis Institute of Health Economics, issuing body.
- Publication:
- Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Eligibility Determination Insurance Coverage Insurance, Health Proprotein Convertase 9 -- antagonists & inhibitors Serine Proteinase Inhibitors -- economics Serine Proteinase Inhibitors -- therapeutic use Economics, Pharmaceutical Formularies as Topic Hypercholesterolemia -- drug therapy Medicaid -- economics Medicare -- economics Private Sector Public Sector Humans Pennsylvania United States
- Genre(s):
- Technical Report
- Abstract:
- Key Findings. A comprehensive review of prior authorization (PA) requirements for a new class of expensive cholesterol-lowering drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has found unusually complex and burdensome demands across public and private insurance plans in the United States. These findings raise concerns that current policies may create undue barriers to care even in medically appropriate patients, particularly since requirements were just as stringent for patients with a genetic condition that creates more clear-cut eligibility for PCSK9 inhibitor treatment.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (2 unnumbered pages))
- Illustrations:
- Illustrations and Portraits
- NLM Unique ID:
- 101731578 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101731578